Related Experiment Video
Updated: Apr 17, 2026
06:08
Establishment and Characterization of Patient-Derived Xenograft Models of Anaplastic Thyroid Carcinoma and Head and Neck Squamous Cell Carcinoma
Published on: June 2, 2023
2.6K
Extrapulmonary small cell carcinoma in head and neck.
R Yasumatsu1, T Nakashima1, M Yamauchi1
1Department of Otorhinolaryngology,Graduate School of Medical Sciences,Kyushu University,Fukuoka,Japan.
The Journal of Laryngology and Otology
|February 24, 2015
Summary
Extrapulmonary small cell carcinoma in the head and neck has a poor prognosis. This review of nine patients found a median survival of 14.5 months, highlighting the need for standardized treatment strategies.
Area of Science:
- Oncology
- Head and Neck Surgery
Background:
- Extrapulmonary small cell carcinoma (EPSCC) management lacks standardization.
- Head and neck region EPSCC presents unique clinical challenges.
Purpose of the Study:
- To review the clinical course and management of head and neck EPSCC.
- To evaluate survival outcomes for patients with head and neck EPSCC.
Main Methods:
- Retrospective review of nine patients diagnosed with head and neck EPSCC.
- Analysis of treatment modalities including surgery, chemotherapy, and chemoradiotherapy.
Main Results:
- Five patients underwent radical surgery with adjuvant therapy.
- Chemotherapy regimens included CPT11 plus cisplatin or VP-16.
- Chemoradiotherapy utilized S-1 or CPT11 plus cisplatin.
- Median overall survival was 14.5 months; 3-year survival rate was 23.7%.
Conclusions:
- Head and neck EPSCC generally has a poor prognosis.
- Current treatment modalities show limited long-term survival.
- Further multicenter studies are essential for improved understanding and treatment strategies.
Keywords:
Treatment
